Key takeaways:IHL-42X met its primary endpoint, producing statistically significant reductions in AHI versus placebo, with some patients showing reductions of up to 83%. Incannex Healthcare Inc announced positive topline results and patient-reported outcomes from its RePOSA Phase 2 clinical trial of IHL-42X, an oral drug candidate for treating obstructive sleep apnea (OSA). The study showed that the fixed-dose combination of dronabinol and acetazolamide achieved statistically significant improvements in key clinical endpoints and was well tolerated by participants. Other key findings from the trial include:Oxygen Desaturation Index (ODI): Both dose groups showed statistically significant improvements in ODI. The low-dose group also showed statistically significant improvements in the Patient Global Impression of Change score.